J&J's Siegel On Brexit: 'Our Objective Is To Minimize Any Disruption'
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J's head of scientific strategy and policy says in an interview that the two-year withdrawal timeline for the UK to leave the EU 'hopefully' provides the firm 'enough time to ensure continuity of business.'
You may also be interested in...
UK Votes To Leave The EU – Where Next For The Life Sciences?
UK vote to leave the EU opens the prospect of years of negotiations over the union's future relationship with one of its most valued member states.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.